Quantum Design China 2022 User Conference was successfully held
Time of Update: 2022-08-30
A total of 11 thematic reports were set up in this user meeting, including the new research and development progress of Quantum Design cryogenic equipment, MPMS3 magnetic measurement system, DynaCool comprehensive physical property measurement system and the principle and usage skills of options, MMPS and MPMS3 user achievement sharing, single crystal growth equipment Technology progress and application, etc.
CO₂-based polycarbonate becomes possible, is bisphenol A still fragrant
Time of Update: 2022-02-16
This research enriches the organic catalytic system of CO₂ and epoxy copolymerization, especially the synthesis of CO₂-based polycarbonate under normal temperature and pressure conditions, which provides a new idea for the efficient conversion of CO₂ .
Express breaks the barrier to protect tumors, and US$65 million helps develop potential "first-in-class" therapies
Time of Update: 2021-11-14
The company plans to use the funds to develop new types of treatments that transform the tumor microenvironment and destroy cancer immune rejection .
Researchers have discovered a key molecule called DDR1 in certain types of breast cancer, which plays an important role in stabilizing tumor extracellular matrix (ECM) .
A large longitudinal study shows that the cross-protective antibodies of dengue fever and Zika virus last longer than expected｜《Science·Translational Medicine
Time of Update: 2021-10-22
Click on the blue text above to follow our new 11-year longitudinal study of more than 4,000 Nicaraguan children.
It unexpectedly showed that antibodies produced by dengue fever and Zika virus infection can prevent these two viruses and maintain Stable for many years, rather than declining rapidly as previously thought .
Where is the road to the development of new drugs for stomach cancer
Time of Update: 2020-09-06
Table 8 Navudan Anti-Key III Clinical Drug Crossing Consulting Guo Lei Team Organizes PD-L1 Expression of PD-L1 Expression of 1% Relapsed or Metastatic Gastric or Gastroesophageal Binding Adenocarcinoma, Medium PFS Feb., OS June, ORR12.061 studies showed that Pembrolizumab single-drug second-line did not significantly improve the total survival of patients with PD-1 CPS scores of 1 compared to standard chemotherapy yew alcohol, and the status of second-line therapy has not yet been established.